JPH08502417A - ヘモフィルス外膜タンパク質 - Google Patents
ヘモフィルス外膜タンパク質Info
- Publication number
- JPH08502417A JPH08502417A JP6512608A JP51260894A JPH08502417A JP H08502417 A JPH08502417 A JP H08502417A JP 6512608 A JP6512608 A JP 6512608A JP 51260894 A JP51260894 A JP 51260894A JP H08502417 A JPH08502417 A JP H08502417A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- outer membrane
- dna
- peptide
- haemophilus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710116435 Outer membrane protein Proteins 0.000 title claims abstract description 86
- 241000606790 Haemophilus Species 0.000 title claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 154
- 241000606768 Haemophilus influenzae Species 0.000 claims abstract description 123
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 92
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 79
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 73
- 229940047650 haemophilus influenzae Drugs 0.000 claims abstract description 49
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 31
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 24
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 24
- 229920001184 polypeptide Polymers 0.000 claims abstract description 20
- 239000012634 fragment Substances 0.000 claims description 134
- 108020004414 DNA Proteins 0.000 claims description 70
- 150000001413 amino acids Chemical class 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 43
- 101150114001 D15 gene Proteins 0.000 claims description 39
- 239000013612 plasmid Substances 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 36
- 230000002163 immunogen Effects 0.000 claims description 35
- 230000014509 gene expression Effects 0.000 claims description 32
- 229960005486 vaccine Drugs 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 25
- 210000002966 serum Anatomy 0.000 claims description 24
- 241000894006 Bacteria Species 0.000 claims description 20
- 230000001681 protective effect Effects 0.000 claims description 18
- 150000004676 glycans Chemical class 0.000 claims description 16
- 229920001282 polysaccharide Polymers 0.000 claims description 16
- 239000005017 polysaccharide Substances 0.000 claims description 16
- 206010022000 influenza Diseases 0.000 claims description 14
- 230000005847 immunogenicity Effects 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- 210000000987 immune system Anatomy 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 230000009466 transformation Effects 0.000 claims description 6
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 108091035707 Consensus sequence Proteins 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000010419 fine particle Substances 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000007963 capsule composition Substances 0.000 claims 1
- 230000014726 immortalization of host cell Effects 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 239000011505 plaster Substances 0.000 claims 1
- 210000004201 immune sera Anatomy 0.000 abstract description 38
- 229940042743 immune sera Drugs 0.000 abstract description 38
- 230000003053 immunization Effects 0.000 abstract description 23
- 238000002649 immunization Methods 0.000 abstract description 23
- 238000004519 manufacturing process Methods 0.000 abstract description 16
- 206010061190 Haemophilus infection Diseases 0.000 abstract description 13
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 239000000356 contaminant Substances 0.000 abstract description 2
- CMEJFHBXHREXBP-AVAZHIDJSA-N 2-[[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-5-amino-5-oxo-2-[[(2s)-1-[(2s)-1-[(2s)-pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]-3-methylbutanoyl]pyrr Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)NCC(O)=O)CCN1C(=O)[C@@H]1CCCN1 CMEJFHBXHREXBP-AVAZHIDJSA-N 0.000 description 212
- 235000018102 proteins Nutrition 0.000 description 60
- 241000588724 Escherichia coli Species 0.000 description 41
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 36
- 239000000427 antigen Substances 0.000 description 34
- 108091007433 antigens Proteins 0.000 description 34
- 102000036639 antigens Human genes 0.000 description 34
- 241000283973 Oryctolagus cuniculus Species 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 26
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 25
- 239000002953 phosphate buffered saline Substances 0.000 description 25
- 239000000523 sample Substances 0.000 description 21
- 108020001507 fusion proteins Proteins 0.000 description 19
- 102000037865 fusion proteins Human genes 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 108010070675 Glutathione transferase Proteins 0.000 description 18
- 102000005720 Glutathione transferase Human genes 0.000 description 17
- 241000700159 Rattus Species 0.000 description 17
- 239000011575 calcium Substances 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 208000031729 Bacteremia Diseases 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 14
- 239000002671 adjuvant Substances 0.000 description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 241000700199 Cavia porcellus Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000003119 immunoblot Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 229920004890 Triton X-100 Polymers 0.000 description 10
- 239000013504 Triton X-100 Substances 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 241000700198 Cavia Species 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 229920002684 Sepharose Polymers 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 230000009257 reactivity Effects 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 108090000190 Thrombin Proteins 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 229960004072 thrombin Drugs 0.000 description 7
- 241001131785 Escherichia coli HB101 Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 210000000447 Th1 cell Anatomy 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000013611 chromosomal DNA Substances 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 208000010899 haemophilus infectious disease Diseases 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 206010033078 Otitis media Diseases 0.000 description 4
- 108050005609 Outer membrane protein assembly factor BamA Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 230000002788 anti-peptide Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 210000004754 hybrid cell Anatomy 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 229910017119 AlPO Inorganic materials 0.000 description 3
- -1 D15 carbohydrate Chemical class 0.000 description 3
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 101710194807 Protective antigen Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000000521 hyperimmunizing effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101000609456 Beet necrotic yellow vein virus (isolate Japan/S) Protein P26 Proteins 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 101000955367 Pseudomonas putida Transcriptional regulatory protein XylR Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000021235 carbamoylation Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150029062 15 gene Proteins 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- KFDPCYZHENQOBV-UHFFFAOYSA-N 2-(bromomethyl)-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1CBr KFDPCYZHENQOBV-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- JAJQQUQHMLWDFB-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-5-phenylpentanoate Chemical compound OC(=O)CC(O)C(N)CC1=CC=CC=C1 JAJQQUQHMLWDFB-UHFFFAOYSA-N 0.000 description 1
- MQWCXKGKQLNYQG-UHFFFAOYSA-N 4-methylcyclohexan-1-ol Chemical compound CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GMGWOTQMUKYZIE-UBHSHLNASA-N Ala-Pro-Phe Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GMGWOTQMUKYZIE-UBHSHLNASA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- VJDOAZKNBQCAGE-LMVFSUKVSA-N D-ribitol 5-phosphate Chemical compound OC[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O VJDOAZKNBQCAGE-LMVFSUKVSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 101150066516 GST gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940124855 Haemophilus influenzae vaccine Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010004718 Lipoglycopeptides Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 208000006816 Neonatal Sepsis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 150000007930 O-acyl isoureas Chemical class 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036422 Postpartum sepsis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000020264 Puerperal Infection Diseases 0.000 description 1
- 244000097202 Rathbunia alamosensis Species 0.000 description 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- AWGTVRDHKJQFAX-UHFFFAOYSA-M chloro(phenyl)mercury Chemical compound Cl[Hg]C1=CC=CC=C1 AWGTVRDHKJQFAX-UHFFFAOYSA-M 0.000 description 1
- 239000007330 chocolate agar Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003283 colorimetric indicator Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 208000001606 epiglottitis Diseases 0.000 description 1
- 229940023064 escherichia coli Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002731 mercury compounds Chemical class 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- SJFKGZZCMREBQH-UHFFFAOYSA-N methyl ethanimidate Chemical compound COC(C)=N SJFKGZZCMREBQH-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- QPJSUIGXIBEQAC-UHFFFAOYSA-N n-(2,4-dichloro-5-propan-2-yloxyphenyl)acetamide Chemical compound CC(C)OC1=CC(NC(C)=O)=C(Cl)C=C1Cl QPJSUIGXIBEQAC-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001254 nonsecretory effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000003571 opsonizing effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 238000007483 tonsillectomy Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.少なくともD15外膜タンパクをコードした部分を有し、(a)図1A〜1 Eのいずれかに記載のDNA配列またはその相補ストランド、および(b)厳し い条件下で(a)に定義したDNA配列にハイブリッド化するDNA配列のいず れかを有する精製および単離した核酸分子、 2.(b)に定義した上記のDNA配列が、(a)に定義した配列と同じ配列を 少なくとも90%有する請求項1に記載の分子 3.(b)に定義した上記のDNA配列が、図1Fに記載する共通配列を含む請 求項1記載の分子。 4.ホストの形質転換に適応する組換えプラスミドであって、組換えプラスミド は請求項1、2または3に記載のDNA分子の少なくとも18bpフラグメント を含むDNAフラグメントを挿入したプラスミドベクターを含む。 5.1993年11月4日に寄託したATCC受入番号75604を有するプラ スミドDS−712−2−1および1993年11月4日に寄託したATCC受 入番号75606を有するプラスミドJB−1042−5−1のいずれかである 請求項4に記載の組換えプラスミド。 6.ホスト細胞の形質転換に適応する組換えベクター であって、組換えベクターは、少なくとも請求項1、2または3に記載のDNA 分子の少なくとも18BPフラグメントを含むDNAフラグメントおよびこれに よりホスト細胞中にコード化した遺伝子生成物の表現のためのDNAフラグメン トに人為的に結合させた表現手段を含む。 7.1993年11月4日に寄託し、ATCC受入番号75605を有するプラ スミドDS−880−1−2であり、インフルエンザ菌SB33のD15遺伝子 生成物をコード化した請求項6に記載の組換えベクタ。 8.上記のDNAフラグメントが少なくとも残基6個のポリペプチドをコード化 している請求項6に記載の組換えベクター。 9.上記のポリペプチドが、表2に記載したもののいずれかである請求項8に記 載の組換えベクター。 10.上記のDNAフラグメントが上記のD15外膜タンパクのコード配列より も大きくない、請求項6、7、8または9に記載の組換えベクター。 11.DNAフラグメントが、さらに上記のホストからの上記の遺伝子生成物の 送り出しのためのリーダー配列をコード化している核酸配列を含む請求項10に 記載の組換えベクター。 12.請求項10または11に記載の組換えベクター 中に含まれるDNAフラグメントによりコード化された精製および単離したタン パク。 13.精製および単離したD15外膜タンパクまたはその部廷 14.D15外膜タンパクがヘモフィルスD15外膜タンパクである請求項13 に記載のタンパク。 15.D15外膜タンパクがインフルエンザ菌D15外膜タンパクである請求項 14に記載のタンパク。 16.インフルエンザ菌がb型インフルエンザ菌株である請求項15に記載のタ ンパク。 17.b型インフルエンザ菌株が、Ca、MinnAおよびイーガン株のいずれ かである請求項16に記載のタンパク。 18.インフルエンザ菌が型別不能インフルエンザ菌株である請求項15に記載 のタンパク。 19.型別不能インフルエンザ菌株が、PAK12085およびSB33株のい ずれかである請求項18に記載のタンパク。 20.請求項11〜19のいずれかに記載のタンパクまたはその部分のアミノ酸 配列または免疫原性を保存している変異体または突然変異体に相当するアミノ酸 配列を有する合成ペプチド。 21.表2に記載のアミノ酸配列のいずれかである請求項20に記載のペプチド 。 22.請求項1〜5のいずれかに記載の核酸分子と、請求項12〜14のいずれ かに記載のタンパクと、請求項20または21に記載のペプチドおよび生理学的 に許容されるキャリヤーとを含む免疫原性組成物。 23.ヘモフィルスにより起きる疾病に対する防御のためにin vivo投与するた めのワクチンとして配合した請求項22に記載の免疫原性組成物。 24.微粒子状調剤、カプセル調剤またはリポソーム調剤として配合した請求項 23に記載の免疫原性組成物。 25.免疫系の所定の細胞または粘液面に投与するために標的分子と組み合わせ る請求項23に記載の免疫原性組成物 26.ヘモフィルス疾病に対する防御的免疫を得るために、請求項22〜25の いずれかに記載の免疫原性組成物の有効量を対象に投与することを含むヘモフィ ルスにより起きる疾病に対する防御を誘発する方法。 27.請求項12〜25のいずれかに記載のタンパク、ペプチドまたは免疫原性 組成物に特異的な免疫血清または抗体。 28.その他のポリペプチドまたはタンパクまたは多糖類にリンクしている請求 項12〜19のいずれかに記載のタンパク、または請求項20または21に記載 のペプチドを含むキメラ分子。 29.上記のその他のポリペプチドまたはタンパクが、病原菌からの表面タンパ クまたはこれに相当するペプチドを含む請求項28に記載のキメラ分子。 30.上記のその他のポリペプチドまたはタンパクが、インフルエンザ菌のP1 、P2またはP6外膜タンパクを含む請求項29に記載のキメラ分子。 31.上記の多糖類がインフルエンザ菌からのPRP分子を含む請求項28記載 のキメラ分子。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929224584A GB9224584D0 (en) | 1992-11-23 | 1992-11-23 | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
GB9224584.4 | 1992-11-23 | ||
PCT/CA1993/000501 WO1994012641A1 (en) | 1992-11-23 | 1993-11-23 | Haemophilus outer membrane protein |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08502417A true JPH08502417A (ja) | 1996-03-19 |
JP2907552B2 JP2907552B2 (ja) | 1999-06-21 |
Family
ID=10725587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6512608A Expired - Lifetime JP2907552B2 (ja) | 1992-11-23 | 1993-11-23 | ヘモフィルス外膜タンパク質 |
Country Status (11)
Country | Link |
---|---|
US (3) | US6013514A (ja) |
EP (1) | EP0668916B1 (ja) |
JP (1) | JP2907552B2 (ja) |
AT (1) | ATE294864T1 (ja) |
AU (1) | AU683435B2 (ja) |
BR (1) | BR9307510A (ja) |
CA (1) | CA2149319C (ja) |
DE (1) | DE69333802T8 (ja) |
GB (1) | GB9224584D0 (ja) |
RU (1) | RU2141528C1 (ja) |
WO (1) | WO1994012641A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003525250A (ja) * | 2000-03-01 | 2003-08-26 | ビナックス インコーポレーティッド | 標的細菌またはその標的糖質抗原成分の存在を検出する方法 |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9205704D0 (en) * | 1992-03-16 | 1992-04-29 | Connaught Lab | High molecular weight membrane proteins of non-typeable haemophilus |
US6361779B1 (en) * | 1993-11-08 | 2002-03-26 | Aventis Pasteur Limited | Transferrin receptor genes |
CN1267553C (zh) | 1993-11-08 | 2006-08-02 | 康诺特实验室有限公司 | 嗜血杆菌属转铁蛋白受体基因 |
US5981503A (en) * | 1994-06-07 | 1999-11-09 | Connaught Laboratories Limited | Analog of Haemophilus Hin47 with reduced protease activity |
US5939297A (en) * | 1994-07-21 | 1999-08-17 | Connaught Laboratories Limited | Analog of haemophilus HIN47 with reduced protease activity |
US5506139A (en) * | 1994-07-21 | 1996-04-09 | Connaught Laboratories Limited | Analog of haemophilus Hin47 with reduced protease activity |
US6153580A (en) * | 1994-07-21 | 2000-11-28 | Loosmore; Sheena M. | Analog of haemophilus Hin47 with reduced protease activity |
NZ291750A (en) * | 1994-07-21 | 1997-10-24 | Connaught Lab | Analogues of haemophilus influenzae hin47 protein with reduced protease activity |
US5681570A (en) | 1995-01-12 | 1997-10-28 | Connaught Laboratories Limited | Immunogenic conjugate molecules |
WO1996032963A1 (en) * | 1995-04-17 | 1996-10-24 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins |
US6355450B1 (en) | 1995-04-21 | 2002-03-12 | Human Genome Sciences, Inc. | Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof |
US5780606A (en) * | 1995-06-07 | 1998-07-14 | Connaught Laboratories Limited | Neisseria meningitidis capsular polysaccharide conjugates |
GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
US6048539A (en) * | 1995-11-02 | 2000-04-11 | Connaught Laboratories Limited | Lactoferrin receptor protein |
US6033877A (en) * | 1995-11-02 | 2000-03-07 | Research Foundation Of State University Of New York | Peptide expression and delivery system |
US6211159B1 (en) | 1997-04-11 | 2001-04-03 | University Of Toronto | Flagellin gene, FlaC of campylobacter |
US5977337A (en) * | 1997-06-03 | 1999-11-02 | Connaught Laboratories Limited | Lactoferrin receptor genes of Moraxella |
US6068993A (en) * | 1997-07-02 | 2000-05-30 | Biobras Sa | Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin |
US6803043B1 (en) * | 1998-06-03 | 2004-10-12 | Glaxosmithkline Biologicals S.A. | Basbo27 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses |
US6824997B1 (en) | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
US9134303B1 (en) | 1998-08-25 | 2015-09-15 | Alere Scarborough, Inc. | ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto |
US6610306B2 (en) * | 1998-10-22 | 2003-08-26 | The University Of Montana | OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof |
US7241449B1 (en) | 1999-04-12 | 2007-07-10 | Aventis Pasteur Limited | Transferrin receptor genes of moraxella |
WO2001048018A1 (en) * | 1999-12-27 | 2001-07-05 | University Of Manitoba | Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens |
US7192725B2 (en) | 2000-05-19 | 2007-03-20 | University Of Toronto | Flagellin gene, flaC of Campylobacter |
GB0022017D0 (en) * | 2000-09-08 | 2000-10-25 | Univ Dundee | Cell assays |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
JP2006506467A (ja) | 2002-08-02 | 2006-02-23 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
CA2808919C (en) | 2005-12-22 | 2016-04-19 | Glaxosmithkline Biologicals S.A. | Streptococcus pneumoniae capsular saccharide vaccine |
ZA200805602B (en) | 2006-01-17 | 2009-12-30 | Arne Forsgren | A novel surface exposed haemophilus influenzae protein (protein E; pE) |
US8697154B2 (en) * | 2007-03-05 | 2014-04-15 | Om Pharma Sa | Bacterial extract for respiratory disorders and process for its preparation |
DK2167121T3 (en) | 2007-06-26 | 2015-11-23 | Glaxosmithkline Biolog Sa | A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
JP2013521770A (ja) | 2010-03-10 | 2013-06-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
WO2012170356A1 (en) | 2011-06-04 | 2012-12-13 | Rochester General Hospital Research Institute | Compositions and methods related to p6 of haemophilus influenzae |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
WO2018219521A1 (en) | 2017-05-30 | 2018-12-06 | Glaxosmithkline Biologicals S.A. | Methods for manufacturing an adjuvant |
JP2021504424A (ja) | 2017-12-01 | 2021-02-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
WO2020030572A1 (en) | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
US20220047690A1 (en) * | 2018-10-15 | 2022-02-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Vaccine polypeptide compositions and methods |
EP3886901A1 (en) | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
CN110540598B (zh) * | 2018-12-20 | 2021-04-30 | 湖北工业大学 | 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法 |
US20220235095A1 (en) | 2019-06-05 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Saponin purification |
GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
WO2024017827A1 (en) | 2022-07-19 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Continuous process for vaccine production |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4888170A (en) * | 1981-10-22 | 1989-12-19 | Research Corporation | Vaccines obtained from antigenic gene products of recombinant genes |
US5194254A (en) | 1986-05-06 | 1993-03-16 | Connaught Laboratories Limited | Enhancement of antigen immunogenicity |
US5013664A (en) * | 1986-05-28 | 1991-05-07 | Brodeur Bernard R | Common protein of Haemophilus influenzae type b identified by a monoclonal antibody |
US5173294A (en) * | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
US5192540A (en) * | 1988-04-19 | 1993-03-09 | American Cyanamid Company | Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine |
CA2006587C (en) * | 1988-12-23 | 2000-01-18 | Robert W. Tolan | Membrane proteins and peptides of haemophilus influenzae type b |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
GB8924473D0 (en) * | 1989-10-31 | 1989-12-20 | Connaught Lab | Outer membrane protein p1 and peptides of haemophilus influenzae b |
ATE156705T1 (de) | 1991-04-02 | 1997-08-15 | Biotech Australia Pty Ltd | Systeme zur oralen freisetzung von mikropartikeln |
US5620896A (en) | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
-
1992
- 1992-11-23 GB GB929224584A patent/GB9224584D0/en active Pending
-
1993
- 1993-11-23 RU RU95117238A patent/RU2141528C1/ru active
- 1993-11-23 EP EP94900671A patent/EP0668916B1/en not_active Expired - Lifetime
- 1993-11-23 CA CA002149319A patent/CA2149319C/en not_active Expired - Lifetime
- 1993-11-23 WO PCT/CA1993/000501 patent/WO1994012641A1/en active IP Right Grant
- 1993-11-23 JP JP6512608A patent/JP2907552B2/ja not_active Expired - Lifetime
- 1993-11-23 AT AT94900671T patent/ATE294864T1/de not_active IP Right Cessation
- 1993-11-23 DE DE69333802T patent/DE69333802T8/de active Active
- 1993-11-23 AU AU55565/94A patent/AU683435B2/en not_active Expired
- 1993-11-23 BR BR9307510A patent/BR9307510A/pt not_active Application Discontinuation
- 1993-11-23 US US08/433,522 patent/US6013514A/en not_active Expired - Lifetime
-
1997
- 1997-10-01 US US08/942,046 patent/US6264954B1/en not_active Expired - Lifetime
-
1998
- 1998-08-18 US US09/135,166 patent/US6083743A/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003525250A (ja) * | 2000-03-01 | 2003-08-26 | ビナックス インコーポレーティッド | 標的細菌またはその標的糖質抗原成分の存在を検出する方法 |
JP2011145301A (ja) * | 2000-03-01 | 2011-07-28 | Binax Inc | 標的細菌またはその標的糖質抗原成分の存在を検出する方法 |
Also Published As
Publication number | Publication date |
---|---|
DE69333802D1 (de) | 2005-06-09 |
US6264954B1 (en) | 2001-07-24 |
DE69333802T8 (de) | 2006-05-11 |
CA2149319C (en) | 2008-10-07 |
JP2907552B2 (ja) | 1999-06-21 |
US6013514A (en) | 2000-01-11 |
EP0668916B1 (en) | 2005-05-04 |
EP0668916A1 (en) | 1995-08-30 |
WO1994012641A1 (en) | 1994-06-09 |
US6083743A (en) | 2000-07-04 |
DE69333802T2 (de) | 2006-01-26 |
GB9224584D0 (en) | 1993-01-13 |
BR9307510A (pt) | 1999-06-01 |
RU2141528C1 (ru) | 1999-11-20 |
AU683435B2 (en) | 1997-11-13 |
ATE294864T1 (de) | 2005-05-15 |
CA2149319A1 (en) | 1994-06-09 |
AU5556594A (en) | 1994-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2907552B2 (ja) | ヘモフィルス外膜タンパク質 | |
JP3771265B2 (ja) | モラクセラ属(Moraxella)の高分子量主要外膜タンパク | |
KR100271888B1 (ko) | 모락셀라 카타랄리스의 유용한 항원과 관련된 방법 및 조성물 | |
RU2194757C2 (ru) | ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ФРАГМЕНТ БЕЛКА РЕЦЕПТОРА ТРАНСФЕРРИНА ШТАММА Haemophilus (ВАРИАНТЫ), ПЛАЗМИДНЫЙ ВЕКТОР (ВАРИАНТЫ), РЕКОМБИНАНТНЫЙ БЕЛОК (ВАРИАНТЫ), ВЫДЕЛЕННЫЙ И ОЧИЩЕННЫЙ БЕЛОК (ВАРИАНТЫ), ИММУНОГЕННАЯ КОМПОЗИЦИЯ И СПОСОБ ПОЛУЧЕНИЯ ВЫДЕЛЕННОГО И ОЧИЩЕННОГО БЕЛКА | |
JPH11507214A (ja) | Hsp70ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー | |
JP2001517091A (ja) | Helicobacter pyloriについての抗原性組成物および検出方法 | |
JP2001503602A (ja) | 非共通形態型好血菌属の高分子量表面タンパク質 | |
KR20060118630A (ko) | 나이제리아 고노리아 또는 나이제리아 메닌지티디스에 대한재조합 필린을 함유한 백신 | |
US7118749B2 (en) | Transferrin receptor genes | |
KR100216390B1 (ko) | 헤모필루스 외부막 단백질 | |
JP2004529601A (ja) | 組換えインフルエンザ菌アドヘシンタンパク質 | |
EP1535928B1 (en) | Vaccine compositions comprising Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis | |
CHONG et al. | Patent 2149319 Summary | |
CHONG et al. | Sommaire du brevet 2149319 | |
RU2196176C2 (ru) | АНАЛОГ HIN47 Haemophilus С РЕДУЦИРОВАННОЙ ПРОТЕАЗНОЙ АКТИВНОСТЬЮ | |
JP4184430B2 (ja) | プロテアーゼ活性低下型のHaemophilus Hin47の類似体 | |
KR100394454B1 (ko) | 트랜스페린수용체유전자들 | |
MXPA97009557A (en) | Members of streptococal thermal shock proteins of the hs family |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090402 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100402 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110402 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120402 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120402 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130402 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130402 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140402 Year of fee payment: 15 |
|
EXPY | Cancellation because of completion of term |